With FDA approval of the first ever drug for NF in hand, it’s more important than ever that NF research funding be secured to expand the clinical pipeline even further, and bring more options to NF patients. During recent visits on the Hill, we’ve advocated for increased funding of NF research of $20 million within the CDMRP (Congressionally Directed Medical Research Programs), highlighting the highly collaborative and efficient research work supported through public and private resources. We’re also proud to have joined the other members of the Defense Health Research Consortium (DHRC), 133 organizations in total, in sending the attached letters to the House and Senate Appropriations Subcommittees on Defense in support of the CDMRP. Please read the letters for more information on the critical importance of this funding, and we’ll continue to provide you with updates on the coordinated effort to secure research funding to benefit patients.
